Johanna Hjalte
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Johanna Hjalte has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Helen Sjögren
Ferring Pharmaceuticals A/S, Amager Strandvej 405, 2770 Kastrup, Denmark
2 shared publications - Marie Wahlgren
Department of Process and Life Science Engineering, Lund University, 221 00 Lund, Sweden
2 shared publications - Andreas Hugerth
Physical Pharmaceutical Chemistry, Uppsala University, Uppsala Biomedical Center, Box 574, S-751 23 Uppsala, Sweden
1 shared publication Anna-Maria Börjesdotter
1 shared publication- Dan Lundberg
Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals Research and Development
1 shared publication - Javier Lagares Martín1 shared publication
Latest Publications
- Open Access
- 1 March 2025
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 107
Interactions between polysorbate and antimicrobial preservatives in aqueous parenteral products
- 1 March 2025
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 107
Open AccessInteractions between polysorbate and antimicrobial preservatives in aqueous parenteral products
- Open Access
- 1 February 2022
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 19 (3) , 904-917
Aggregation Behavior of Structurally Similar Therapeutic Peptides Investigated by 1H NMR and All-Atom Molecular Dynamics Simulations
Understanding of peptide aggregation propensity is an important aspect in pharmaceutical development of peptide drugs. In this work, methodologies based on all-atom molecular dynamics (AA-MD) simulations and 1H NMR (in neat H2O) were evaluated as tools for identification and investigation of peptide aggregation. A series of structurally similar, pharmaceutically relevant peptides with known differences in aggregation behavior (D-Phe6-GnRH, ozarelix, cetrorelix, and degarelix) were investigated. The 1H NMR methodology was used to systematically investigate variations in aggregation with peptide concentration and time. Results show that 1H NMR can be used to detect the presence of coexisting classes of aggregates and the inclusion or exclusion of counterions in peptide aggregates. Interestingly, results suggest that the acetate counterions are included in aggregates of ozarelix and cetrorelix but not in aggregates of degarelix. The peptides investigated in AA-MD simulations (D-Phe6-GnRH, ozarelix, and cetrorelix) showed the same rank order of aggregation propensity as in the NMR experiments. The AA-MD simulations also provided molecular-level insights into aggregation dynamics, aggregation pathways, and the influence of different structural elements on peptide aggregation propensity and intermolecular interactions within the aggregates. Taken together, the findings from this study illustrate that 1H NMR and AA-MD simulations can be useful, complementary tools in early evaluation of aggregation propensity and formulation development for peptide drugs.
- 1 February 2022
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 19 (3) , 904-917
Open AccessAggregation Behavior of Structurally Similar Therapeutic Peptides Investigated by 1H NMR and All-Atom Molecular Dynamics Simulations
Understanding of peptide aggregation propensity is an important aspect in pharmaceutical development of peptide drugs. In this work, methodologies based on all-atom molecular dynamics (AA-MD) simulations and 1H NMR (in neat H2O) were evaluated as tools for identification and investigation of peptide aggregation. A series of structurally similar, pharmaceutically relevant peptides with known differences in aggregation behavior (D-Phe6-GnRH, ozarelix, cetrorelix, and degarelix) were investigated. The 1H NMR methodology was used to systematically investigate variations in aggregation with peptide concentration and time. Results show that 1H NMR can be used to detect the presence of coexisting classes of aggregates and the inclusion or exclusion of counterions in peptide aggregates. Interestingly, results suggest that the acetate counterions are included in aggregates of ozarelix and cetrorelix but not in aggregates of degarelix. The peptides investigated in AA-MD simulations (D-Phe6-GnRH, ozarelix, and cetrorelix) showed the same rank order of aggregation propensity as in the NMR experiments. The AA-MD simulations also provided molecular-level insights into aggregation dynamics, aggregation pathways, and the influence of different structural elements on peptide aggregation propensity and intermolecular interactions within the aggregates. Taken together, the findings from this study illustrate that 1H NMR and AA-MD simulations can be useful, complementary tools in early evaluation of aggregation propensity and formulation development for peptide drugs.